TY - JOUR
T1 - Very low-dose lenalidomide therapy for elderly multiple myeloma patients.
AU - Minagawa, Kentaro
AU - Kawano, Hiroki
AU - Suzuki, Takuma
AU - Inagaki, Tadahiro
AU - Kishi, Minoru
AU - Hirata, Tamaki
AU - Kimura, Sachiko
AU - Takechi, Miho
AU - Koide, Toru
AU - Iwai, Masahide
AU - Katayama, Yoshio
AU - Matsui, Toshimitsu
PY - 2013/5
Y1 - 2013/5
N2 - Lenalidomide treatment for refractory or relapsed multiple myeloma in elderly patients may be feasible in an outpatient setting. However, difficulties have been associated with the management of adverse effects. Therefore, a dose reduction in lenalidomide has been recommended in some cases. In this report, we encountered the successful treatment of myeloma in 6 elderly patients (aged above 70 years) with very low-dose lenalidomide (5 mg daily). Four patients exhibited more than a partial response with an 8.6 months median follow-up period, which was comparable with previous findings. The major adverse effect observed was infection, which occurred during the first several cycles. Others were less toxic, especially the absence of grade 3/4 toxicities for hematological adverse effects.Although a dose reduction in lenalidomide therapy for elderly patients is controversial, a very low dose could be safe and effective. Our group is currently conducting a multi-center prospective trial to evaluate the efficacy of low-dose lenalidomide therapy.
AB - Lenalidomide treatment for refractory or relapsed multiple myeloma in elderly patients may be feasible in an outpatient setting. However, difficulties have been associated with the management of adverse effects. Therefore, a dose reduction in lenalidomide has been recommended in some cases. In this report, we encountered the successful treatment of myeloma in 6 elderly patients (aged above 70 years) with very low-dose lenalidomide (5 mg daily). Four patients exhibited more than a partial response with an 8.6 months median follow-up period, which was comparable with previous findings. The major adverse effect observed was infection, which occurred during the first several cycles. Others were less toxic, especially the absence of grade 3/4 toxicities for hematological adverse effects.Although a dose reduction in lenalidomide therapy for elderly patients is controversial, a very low dose could be safe and effective. Our group is currently conducting a multi-center prospective trial to evaluate the efficacy of low-dose lenalidomide therapy.
UR - http://www.scopus.com/inward/record.url?scp=84893110346&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893110346&partnerID=8YFLogxK
M3 - Article
C2 - 23727684
AN - SCOPUS:84893110346
SN - 0485-1439
VL - 54
SP - 457
EP - 462
JO - [Rinshō ketsueki] The Japanese journal of clinical hematology
JF - [Rinshō ketsueki] The Japanese journal of clinical hematology
IS - 5
ER -